Effectiveness and Safety Profile of Ginkgo biloba Standardized Extract (EGb761®) in Patients with Amnestic Mild Cognitive Impairment
- 3 November 2021
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in CNS & Neurological Disorders - Drug Targets
- Vol. 20 (4), 378-384
- https://doi.org/10.2174/1871527320666210208125524
Abstract
Background: Ginkgo biloba is a common symptomatic treatment for cognitive impairment, although data on its efficacy are controversial. Objective: The aim of the current study was to evaluate the effectiveness of standardized Ginkgo biloba extract EGb761® (Tanakan®) for the improvements of cognitive functions over 24 months in a local cohort of patients diagnosed with amnestic mild cognitive impairment (aMCI). Methods: This multicentre non-interventional study included 500 eligible patients with a MCI treated with 120 mg/day standardized Ginkgo biloba extract EGb761® (Tanakan®). Patients were evaluated using several scales for assessment of cognition, memory, activities of daily living, and depression (MMSE, FAQ, CGI, HAM-D) at baseline and every 6 months after that for a 24-month period. The median change in MMSE at the 24-month follow-up was the primary outcome of the study. Results: A statistically significant increase of 2 points in the median MMSE score was obtained. In patients with other concomitant cognitive disorders, the improvement in MMSE was less significant. Tanakan® improved memory impairment (using the delayed recall test) and the ability to accomplish activities of daily living (mean FAQ score, 1.7); it also decreased the severity of depression (mean HAM-D score, 2.4) at the end of the study. More than 80% of the patients showed minimal improvement of their condition as assessed by the CGI-Improvement Scale. Conclusions: The administration of EGb761® (Tanakan®) led to a significant improvement of cognitive decline, memory, activities of daily living, and depression in subjects with aMCI over 24 months.Keywords
This publication has 30 references indexed in Scilit:
- Assessment of mild cognitive impairment with mini mental state examination among adults in Southeast NigeriaAnnals of Medical and Health Sciences Research, 2012
- Efficacy and Tolerability of a Once Daily Formulation of Ginkgo biloba Extract EGb 761® in Alzheimer's Disease and Vascular Dementia: Results from a Randomised Controlled TrialPharmacopsychiatry, 2011
- Utility of the Functional Activities Questionnaire for Distinguishing Mild Cognitive Impairment From Very Mild Alzheimer DiseaseAlzheimer Disease & Associated Disorders, 2010
- Ginkgo biloba Extract in Alzheimer’s Disease: From Action Mechanisms to Medical PracticeInternational Journal of Molecular Sciences, 2010
- Ginkgo biloba for Preventing Cognitive Decline in Older AdultsA Randomized TrialJAMA, 2009
- Mild Cognitive ImpairmentArchives of Neurology, 2009
- Leichte kognitive Beeinträchtigung mit Vorzeichen rascher VerschlechterungDeutsche Medizinische Wochenschrift (1946), 2008
- The Ginkgo Evaluation of Memory (GEM) study: Design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementiaContemporary Clinical Trials, 2006
- Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive ImpairmentJournal of Internal Medicine, 2004
- A New Clinical Scale for the Staging of DementiaThe British Journal of Psychiatry, 1982